GuardantINFORM™ is an unparalleled real-world evidence solution that powers critical decision-making in research, oncology drug development, and commercialization.
500k+
Unique patient profiles.
References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023.
2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test.
August 7, 2020. Updated
August 11, 2020. Accessed April 2, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test
3. Guardant Health data on file. Guardant Health, Inc. Redwood City, CA.
60+
Patients sequenced with
Advanced/metastatic solid tumor types tested
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma GuardantINFORM™ for BioPharma
>24K+
